Cohance Lifesciences Ltd

Cohance Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Cohance Lifesciences Ltd

₹ 428 0.07%
19 May 3:49 p.m.
cohance.com BSE: 543064 NSE: COHANCE
About

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]

Key Points

Market Position
The company has established a strong presence in the contract research and manufacturing services (CRAMS) sector and is one of the top 5 providers of high-end intermediates to innovators in India. [1]

Website BSE NSE
  • Market Cap ₹ 16,387 Cr.
  • Current Price ₹ 428
  • High / Low ₹ 1,180 / 267
  • Stock P/E 65.5
  • Book Value ₹ 117
  • Dividend Yield 0.00 %
  • ROCE 10.4 %
  • ROE 7.36 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 11.0% over last 3 years.
  • Debtor days have increased from 80.9 to 115 days.
  • Working capital days have increased from 136 days to 206 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty MNC Nifty500 Shariah

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
364 344 225 213 253 488 594 653 769 484 498 482 568
187 174 127 144 180 363 391 421 546 379 367 379 451
Operating Profit 177 170 97 69 73 125 204 233 223 104 131 103 117
OPM % 49% 49% 43% 32% 29% 26% 34% 36% 29% 22% 26% 21% 21%
11 10 14 14 17 19 16 21 -8 5 26 1 -17
Interest 5 1 0 2 2 10 9 10 7 7 5 5 5
Depreciation 11 11 10 11 17 31 35 38 43 31 31 33 38
Profit before tax 172 168 101 70 71 103 175 206 166 71 121 65 56
Tax % 25% 26% 26% 25% 25% 27% 21% 25% 26% 26% 22% 28% 39%
130 124 75 52 53 75 139 154 123 53 94 47 35
EPS in Rs 5.11 4.88 2.94 2.06 2.09 2.96 5.46 6.04 4.82 1.37 2.46 1.24 0.90
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 5m Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
378 834 1,010 1,320 1,330 1,051 1,094 2,030
206 449 567 738 739 645 731 1,576
Operating Profit 172 385 443 582 591 406 363 454
OPM % 45% 46% 44% 44% 44% 39% 33% 22%
1 18 14 188 45 57 54 15
Interest 3 22 12 9 13 7 8 22
Depreciation 12 24 32 39 43 55 57 134
Profit before tax 158 358 414 722 579 400 351 314
Tax % 31% 24% 25% 23% 25% 26% 23% 27%
109 270 309 558 433 296 272 229
EPS in Rs 10.61 12.12 21.92 16.99 11.65 10.67 5.98
Dividend Payout % 0% 24% 16% 23% 35% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 15%
3 Years: 15%
TTM: 86%
Compounded Profit Growth
10 Years: %
5 Years: -4%
3 Years: -16%
TTM: -8%
Stock Price CAGR
10 Years: %
5 Years: -3%
3 Years: -3%
1 Year: -60%
Return on Equity
10 Years: %
5 Years: 17%
3 Years: 11%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 0.00 13 25 25 25 25 25 38
Reserves 578 770 1,040 1,495 1,724 2,003 2,290 4,442
83 186 143 97 70 65 99 146
123 142 151 187 139 121 174 487
Total Liabilities 783 1,111 1,359 1,805 1,958 2,214 2,588 5,113
271 357 441 534 512 670 685 2,290
CWIP 111 102 96 30 165 179 254 144
Investments 7 276 426 600 710 893 1,116 1,187
394 376 395 641 571 473 533 1,493
Total Assets 783 1,111 1,359 1,805 1,958 2,214 2,588 5,113

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
50 359 330 270 493 376 301 390
-65 -367 -258 -90 -237 -362 -321 -204
26 9 -77 -156 -243 -40 21 -203
Net Cash Flow 11 1 -4 23 13 -26 1 -18
Free Cash Flow -6 256 219 195 348 324 162 237
CFO/OP 49% 116% 99% 72% 108% 119% 105% 100%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 142 51 37 65 30 46 81 115
Inventory Days 556 278 243 259 284 268 188 302
Days Payable 190 113 100 97 61 49 87 145
Cash Conversion Cycle 509 217 180 228 253 265 182 272
Working Capital Days 205 64 56 107 99 108 94 206
ROCE % 46% 39% 50% 34% 21% 16% 10%

Insights

In beta
Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2025
Patented Commercial Molecules (Pharma CDMO)
Number

Log in to view insights

Please log in to see hidden values.

Login
Phase III Molecules (Pharma CDMO Pipeline)
Number
USFDA Approved Manufacturing Sites
Number
ANDA Portfolio (Partnered and Owned)
Number
Phase III Intermediates
Number
Total Active Projects Pipeline (CDMO)
Number
Working Capital Days
Days
Total Manufacturing Capacity (Commercial)
kL
DMF Filings (Yearly)
Number
Niche Tech Contribution to CDMO Revenue
Percentage
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

9 Recently
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
60.00% 60.00% 60.00% 50.10% 50.10% 50.10% 50.10% 50.10% 66.41% 57.49% 57.49% 57.49%
9.50% 10.01% 10.14% 9.54% 9.80% 10.70% 10.84% 11.05% 7.23% 6.51% 6.01% 5.59%
10.63% 14.13% 15.94% 17.24% 17.42% 16.95% 16.67% 16.60% 11.40% 20.81% 21.57% 21.79%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
19.88% 15.85% 13.93% 23.11% 22.67% 22.26% 22.37% 22.24% 14.95% 15.16% 14.91% 15.11%
No. of Shareholders 72,16773,71570,05268,93265,77769,33784,21086,32580,91075,28481,87785,230

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls